Cited by 101Lipoproteins and Cardiovascular HealthCardiac Imaging and DiagnosticsHealth Systems, Economic Evaluations, Quality of Life

Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines

Open access
Hong, Jonathan C., Blankstein, Ron, Shaw, Leslee J., Padula, William V., Arrieta, Alejandro, Fialkow, Jonathan A., Blumenthal, Roger S., Blaha, Michael J. +2 more·2017·JACC: Cardiovascular Imaging

Abstract

This review evaluates the cost-effectiveness of using coronary artery calcium (CAC) to guide long-term statin therapy compared with treating all patients eligible for statins according to 2013 American College of Cardiology/American Heart Association cholesterol management guidelines for atherosclerotic cardiovascular disease. The authors used a microsimulation model to compare costs and effectiveness from a societal perspective over a lifetime horizon. Both strategies resulted in similar costs and quality-adjusted life years (QALYs). CAC resulted in increased costs (+$81) and near-equal QALY (+0.01) for an incremental cost-effectiveness ratio of $8,100/QALY compared with the treat-all strategy. For 10,000 patients, the treat-all strategy would theoretically avert 21 atherosclerotic cardiovascular disease events, but would add 47,294 person-years of statins. With CAC costs <$100, and higher cost and/or disutility associated with statin therapy, CAC strategy was favored. These findings suggest the economic value of both approaches were similar. Clinicians should account for individual preferences in context of shared decision making when choosing the most appropriate strategy to guide statin decisions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcmg.2017.04.014

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 58 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Hong, J. C., Blankstein, R., Shaw, L. J., Padula, W. V., Arrieta, A., Fialkow, J. A., Blumenthal, R. S., Blaha, M. J., Krumholz, H. M., & Nasir, K.
Affiliations
  • Johns Hopkins University (US)
  • Brigham and Women's Hospital (US)
  • Emory University (US)
  • Florida International University (US)
  • Baptist Hospital of Miami (US)
  • Yale New Haven Hospital (US)
Corresponding author
Nasir, Khurram
Venue
JACC: Cardiovascular Imaging
Publisher
Elsevier BV
Published
2017-08
Volume
10
Issue
8
Pages
938-952
ISSN
  • 1876-7591 (ISSN-L)
  • 1936-878X
OpenAlex
W2744830475
Cited by
101
References
58
Citations by year
2026: 6 · 2025: 6 · 2024: 7 · 2023: 8 · 2022: 9 · 2021: 25 · 2020: 13 · 2019: 13 · 2018: 11 · 2017: 2 · 2016: 1
FWCI
2.26
Type
journal article
Language
en
Open access
Locations
  • JACC. Cardiovascular imaging (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Johns Hopkins University
  • Regeneron Pharmaceuticals
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
coronary artery calcium, statin therapy, cost-effectiveness, atherosclerotic cardiovascular disease, quality-adjusted life years, microsimulation model, shared decision-making, cardiovascular risk stratification
MeSH terms
Clinical Decision-Making, Aged, Aged, 80 and over, American Heart Association, Bayes Theorem, Computer Simulation, Coronary Artery Disease, Coronary Vessels, Cost-Benefit Analysis, Decision Support Techniques, Female, Humans, Male, Middle Aged, Monte Carlo Method, Predictive Value of Tests, Quality of Life, Time Factors, United States, Multivariate Analysis, Drug Costs, Treatment Outcome, Coronary Angiography, Practice Guidelines as Topic, Models, Economic, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Guideline Adherence, Vascular Calcification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review